alogliptin + glimepiride

Alogliptin + glimepiride is a fixed-dose oral combination therapy used to manage type 2 diabetes mellitus. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin levels (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Glimepiride is a sulfonylurea that stimulates pancreatic beta cells to secrete insulin by inhibiting ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. The combination targets different mechanisms in glucose regulation, providing improved glycemic control for patients inadequately managed on monotherapy or lifestyle interventions alone[3][4][6][7].